Teva Pharmaceutical Industries (TEVA) Operating Expenses (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Operating Expenses for 18 consecutive years, with $1.3 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses rose 34.2% year-over-year to $1.3 billion; the trailing twelve-month figure through Jun 2026 stood at $4.4 billion (up 16.68% YoY), and the FY2025 full-year result was $4.0 billion, up 7.32% from the prior year.
• Operating Expenses grew to $1.3 billion in Q2 2026 per TEVA's latest filing, from $1.0 billion in the prior quarter.
• Across five years, Operating Expenses topped out at $1.3 billion in Q2 2026 and bottomed at $822.0 million in Q3 2022.
• Historically, Operating Expenses has averaged $939.1 million across 5 years, with a median of $914.5 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Operating Expenses fell 7.82% in 2022, then soared 34.2% in 2026.
• Over 5 years, Operating Expenses stood at $837.0 million in 2022, then gained by 7.77% to $902.0 million in 2023, then climbed by 5.54% to $952.0 million in 2024, then gained by 17.65% to $1.1 billion in 2025, then advanced by 14.91% to $1.3 billion in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $1.3 billion, $1.0 billion, and $1.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.